Download

Full Text

• Giachetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000; 18(1): 136-147. PMID: 10623704
• De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as firstline treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18 (16): 2938-2947. PMID: 10944126
• Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004; 22 (11): 2084-2091. PMID: 15169795
• Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, et al. Phase III randomised trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'italia Meridonale. J Clin Oncol. 2005; 23 (22): 4866-4875. PMID: 15939922
• Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003; 3 (5): 330-338 PMID: 12724731
• Marcuello E, Altes A, Menoyo A, Rio ED, Baiget M. Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother Pharmacol. 2006; 57 (6): 835-840. PMID: 16187112
• Sharma R, Hoskins JM, Rivory LP, Zucknick M, London R, Liddle C, et al. Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphisms and Toxicity to Capecitabine in Advanced Colorectal Cancer Patients. Clin Cancer Res. 2008; 14 (3): 817-825 doi: 10.1158/1078-0432.CCR-07-0425 PMID: 18245544
• Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol. 2005; 23 (7): 1365-1369. PMID: 15735113
• Etienne-Grimaldi M-C, Francoual M, Formento JL, Milano G. Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer. Pharmacogenomics. 2007; 8 (11): 1561-1566. PMID: 18034621
• Etienne-Grimaldi MC, Bennouna J, Formento JL, Douillard JY, Francoual M, Hennebelle I, et al. Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan. Br J Clin Pharmacol. 2012; 73 (5): 776-785. doi: 10.1111/j.1365-2125.2011.04141.x PMID: 22486600
• Thomas F, Motsinger-Reif AA, Hoskins JM, Dvorak A, Roy S, Alyasiri A, et al. Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. Br J Cancer. 2011; 105 (11): 1654-1662. doi: 10.1038/bjc.2011.442 PMID: 22045187
• Etienne MC, Formento JL, Chazal M, Francoual M, Magne N, Formento P, et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics. 2004; 14 (12): 785-792. PMID: 15608557
• Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol. 2007; 25 (10): 1247-1254. PMID: 17401013
• Capitain O, Boisdron-Celle M, Poirier AL, Abadie-Lacourtoisie S, Morel A, Gamelin E. The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer. Pharmacogenomics J. 2008; 8 (4): 256-267. PMID: 17700593
• Deenen MJ, Rosing H, Hillebrand J, Schellens JH, Beijnen JH. Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2013; 913-914: 30-40. doi: 10.1016/j.jchromb.2012.11.033 PMID: 23270936
• Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987; 47 (8): 2203-2206. PMID: 3829006
• Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A, et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res. 2011; 17 (10): 3455-3468. doi: 10.1158/1078-0432.CCR-10-2209 PMID: 21498394
• Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, et al. Upfront genotyping of DPYD∗2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol. 2016; 34(3): 227-234. doi: 10.1200/JCO.2015.63.1325 PMID: 26573078
• Ciccolini J, Mercier C, Blachon MF, Favre R, Durand A, Lacarelle B. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity. J Clin Pharm Ther. 2004; 29 (4): 307-315. PMID: 15271097
• Lostia AM, Lionetto L, Ialongo C, Gentile G, Viterbo A, Malaguti P, et al. A liquid chromatography-tandem mass spectrometry method for the determination of 5-Fluorouracil degradation rate by intact peripheral blood mononuclear cells. Ther Drug Monit. 2009; 31(4): 482-488. doi: 10.1097/FTD.0b013e3181ae4516 PMID: 19571774
• Gentile G, Botticelli A, Lionetto L, Mazzuca F, Simmaco M, Marchetti P, et al. Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DYPD haplotype to improve toxicity prediction. Pharmacogenomics J. 2015 Jul 28. doi: 10.1038/tpj.2015.56
• Mazzuca F, Borro M, Botticelli A, Mazzotti E, Marchetti L, Gentile G, et al. Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort. Oncotarget. 2016 Mar 8. doi: 10.18632/oncotarget.7991
• Joerger M, Huitema AD, Boot H, Cats A, Doodeman VD, Smits PH, et al. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer Chemother Pharmacol. 2015; 75(4): 763-772. doi: 10.1007/s00280-015-2698-7 PMID: 25677447
• Loganayagam A, Arenas Hernandez M, Corrigan A, Fairbanks L, Lewis CM, Harper P, et al. Pharmacogenetic variants in the DYPD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer. 2013; 108 (12): 2505-2515. doi: 10.1038/bjc.2013.262 PMID: 23736036
• Chua W, Goldstein D, Lee CK, Dhillon H, Michael M, Mitchell P, et al. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br J Cancer. 2009; 101 (6): 998-1004. doi: 10.1038/sj.bjc.6605239 PMID: 19672255
• Sharma R, Hoskins JM, Rivory LP, Zucknick M, London R, Liddle C, et al. Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphisms and Toxicity to Capecitabine in Advanced Colorectal Cancer Patients. Clin Cancer Res 2008; 14 (3): 817-825. doi: 10.1158/1078-0432.CCR-07-0425 PMID: 18245544
• Rosmarin D, Palles C, Church D, Domingo E, Jones A, Jonhstone et al Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol. 2014; 32 (10): 1031-1039. doi: 10.1200/JCO.2013.51.1857 PMID: 24590654
• Afzal S, Gusella M, Vainer B, Vogel UB, Andersen JT, Broedbaek K, et al. Combinations of polymorphisms in genes involved in the 5-Fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients. Clin Cancer Res. 2011; 17(11): 3822-3829. doi: 10.1158/1078-0432.CCR-11-0304 PMID: 21471424
• Leung HW, Chan AL. Association and prediction of severe 5-fluorouracil toxicity with dihydropyrimidine dehydrogenase gene polymorphisms: A meta-analysis. Biomed Rep. 2015; 3(6): 879-883. PMID: 26623034
• Meulendijks D, Henricks LM, Sonke GS, Deneen MJ, Froehlich TK, Amstutz U, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>Aas predictors of severe fluoropyri-midine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015; 16(16): 1639-1650. doi: 10.1016/S1470-2045(15)00286-7 PMID: 26603945
• Toffoli G, Giodini L, Buonadonna A, Berretta M, De Paoli A, Scalone S, et al. Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines. Int J Cancer. 2015; 137(12): 2971-80. doi: 10.1002/ijc.29654 PMID: 26099996
• Lee AM, Shi Q, Pavey E, Alberts SR, Sargent DJ, Sinicrope FA, et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst. 2014; 106(12).
• Rosmarin D, Palles C, Pagnamenta A, Kaur K, Pita G, Martin M, et al. A candidate gene study of cape-citabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. Gut. 2015; 64(1): 111-120. doi: 10.1136/gutjnl-2013-306571 PMID: 24647007
• Huang K, Shen Y, Zhang F, Wang S, Wei X. Evaluation of effects of thymidylate synthase and excision repair cross-complementing 1 polymorphism on chemotherapy outcome in patients with gastrointestinal tumors using peripheral venous blood. Oncol Lett. 2016; 11(5): 3477-3482. PMID: 27123139
• Wu NC, Su SM, Lin TJ, Chin J, Hou CF, Yang JY, et al. Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and fluorouracil-based treatment in Taiwan colorectal cancer. Anticancer Drugs. 2015; 26(8): 888-93. doi: 10.1097/CAD.0000000000000261 PMID: 26111049
• Fernandez-Peralta AM, Daimiel L, Nejda N, Iglesias D, Medina Arana V, Gonzalez-Aguilera JJ. Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epige-netic characteristic of tumors, and response to chemotherapy. Int J Colorectal Dis. 2010; 25(2): 141-151. doi: 10.1007/s00384-009-0779-y PMID: 19669769
• Yhim HY, Cho SH, Kim SY, Cho IS, Lee KT, Lee WS, et al. Prognostic implications of thymidylate synthase gene polymorphisms in patients with advanced small bowel adenocarcinoma treated with first-line fluoropyrimidine-based chemotherapy. Oncol Rep. 2015; 34(1): 155-64. doi: 10.3892/or.2015.3954 PMID: 25955097
• Sun W, Yan C, Jia S, Hu J. Correlation analysis of peripheral DPYD gene polymorphism with 5-fluorouracil susceptibility and side effects in colon cancer patients. Int J Clin Exp Med. 2014; 7(12): 5857-5861. PMID: 25664120
• Zhao J, Li W, Zhu D, Yu Q, Zhang Z, Sun M, et al. Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer. Med Oncol. 2014; 31(1): 802. doi: 10.1007/s12032-013-0802-6 PMID: 24338217
• Kumamoto K, Ishibashi K, Okada N, Tajima Y, Kuwabara K, Kumagai Y, et al. Polymorphisms of GSTP1, ERCC2 and TS-3'UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients. Oncol Lett. 2013; 6(3): 648-654. PMID: 24137384
• Jang MJ, Kim JW, Jeon YJ, Chong SY, Hong SP, Hwang SG, et al. Polymorphisms of folate metabolism-related genes and survival of patients with colorectal cancer in the Korean population. Gene. 2014; 533(2): 558-564. doi: 10.1016/j.gene.2013.09.056 PMID: 24100087
• Sulzyc-Bielicki D, Binczak-Kuleta A, Kaczmarczyk M, Pioch W, Machoy-Mokrzynska A, Ciechanowicz A, et al. Thymidylate synthase gene polymorphism and survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Genet Test Mol Biomarkers. 2013; 17(11): 799-806. doi: 10.1089/gtmb.2013.0171 PMID: 23968134
• Teh LK, Hamzah S, Hashim H, Bannur Z, Zakaria ZA, Hasbullani Z, Shia JK, Fijeraid H, Md Nor A, Zailani M, Ramasamy P, Ngow H, Sood S, Salleh MZ. Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients. Ther Drug Monit. 2013; 35(5): 624-630. doi: 10.1097/FTD.0b013e318290acd2 PMID: 23942539
• Wang YC, Xue HP, Wang ZH, Fang JY. An integrated analysis of the association between Ts gene polymorphisms and clinical outcome in gastric and colorectal cancer patients treated with 5-FU-based regimens. Mol Biol Rep. 2013; 40(7): 4637-4644. doi: 10.1007/s11033-013-2557-8 PMID: 23645036
• Negandhi AA, Hyde A, Dicks E, Pollett W, Younghusband BH, Parfrey P, et al. MTHFR Glu429Ala and ERCC5 His46His polymorphisms are associated with prognosis in colorectal cancer patients: analysis of two independent cohorts from Newfoundland. PLoS One. 2013; 8(4): e61469. doi: 10.1371/journal.pone.0061469 PMID: 23626689
• Zhu L, Wang F, Hu F, Wang Y, Li D, Dong X, et al. Association between MTHFR polymorphisms and overall survival of colorectal cancer patients in Northeast China. Med Oncol. 2013; 30(1): 467. doi: 10.1007/s12032-013-0467-1 PMID: 23392576
• Ruzzo A, Graziano F, Loupakis F, Santini D, Catalano V, Bisonni R, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J. 2008; 8(4): 278-288. PMID: 17549067
• Seck K, Riemer S, Kates R, Ulrich T, Lutz V, Harbeck N, et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin Cancer Res. 2005; 11(16): 5886-5892. PMID: 16115930
• Marcuello E, Altes A, Menoyo A, Rio ED, Baiget M. Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother Pharmacol 2006; 57 (6): 835-40. PMID: 16187112
• Suh KW, Kim JH, Kim DY, Kim BY, Lee C, Choi S. Which gene is a dominant predictor of response during FOLFOX chemotherapy, the MTHFRorXRCC1 gene? Ann Surg Oncol. 2006; 13 (11): 1379-1385. PMID: 17009149
• Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, et al. Pharmacogenomic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol. 2007; 25 (10): 1247-1254. PMID: 17401013
• Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol. 2005; 23 (7): 1365-1369. PMID: 15735113
• Etienne-rimaldi M-C, Francoual M, Formento JL, Milano G. Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer. Pharmacogenomics. 2007; 8 (11): 1561-1566. PMID: 18034621
• Zhang W, Press OA, Haiman CA, Yang DY, Gordon MA, Fazzone W, et al. Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colorectal cancer. J Clin Oncol. 2007; 25 (24): 3726-3731. PMID: 17704422
• Sakamoto E, Nagase H, Kobunai T, Oie S, Oka T, Fukushima M, et al. Orotate phosphoribosyltrasfer-ase expression level in tumors is a potential determinant of the efficacy of 5-fluorouracil. Biochem Bio-phys Res Commun. 2007; 363 (1): 216-222. PMID: 17854773
• Tsunoda A, Nakao K, Watanabe M, Matsui M, Ooyama A, Kusano M. Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucov-orin: a prospective study. Ann Oncol. 2011; 22 (2): 355-361. doi: 10.1093/annonc/mdq358 PMID: 20647221
• Furuse H, Hirano Y, Harada M, Hong Ming L, Aoki T, Kurita Y, et al. Significance of 5-fluorouracil-related enzyme activities in predicting sensitivity to 5-fluorouracil in bladder carcinoma. Anticancer Res. 2009; 29 (4): 1001-1008. PMID: 19414338
• Ochiai T, Umeki M, Miyake H, Iida T, Okumura M, Ohno K, et al. Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer. Oncol Rep. 2014; 32 (3): 887-892. doi: 10.3892/or.2014.3299 PMID: 24994673